Antibodies deplete cancer cells in mice and human cell lines; reach previously inaccessible targets

(American Association for the Advancement of Science) Three studies - one each in Science, Science Translational Medicine, and Science Immunology - reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases.